Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 15784

1.

Serum adipocyte fatty acid-binding protein levels: an indicator of non-alcoholic fatty liver disease in Chinese individuals.

Xu Y, Ma X, Pan X, He X, Wang Y, Bao Y.

Liver Int. 2018 Dec 16. doi: 10.1111/liv.14021. [Epub ahead of print]

PMID:
30554468
2.

Lipidomic analysis reveals the efficiency of Eclipta prostrata on diet-induced nonalcoholic fatty liver disease in rats.

Hussein NS, S Helmy A, Sherif NM, Ghanem HZ, A Ibrahim N, El Gendy ANG, Abdel-Hamid AZ.

J Pharm Biomed Anal. 2018 Nov 30;165:224-232. doi: 10.1016/j.jpba.2018.11.060. [Epub ahead of print]

PMID:
30553982
3.

Primary cultured neuronal networks and type 2 diabetes model mouse fatty liver tissues in aqueous liquid observed by atmospheric SEM (ASEM): Staining preferences of metal solutions.

Sato C, Yamazawa T, Ohtani A, Maruyama Y, Memtily N, Sato M, Hatano Y, Shiga T, Ebihara T.

Micron. 2018 Nov 23;118:9-21. doi: 10.1016/j.micron.2018.11.005. [Epub ahead of print]

PMID:
30553186
4.

Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease.

Fang C, Cai X, Hayashi S, Hao S, Sakiyama H, Wang X, Yang Q, Akira S, Nishiguchi S, Fujiwara N, Tsutsui H, Sheng J.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec 12. pii: S1388-1981(18)30370-6. doi: 10.1016/j.bbalip.2018.12.003. [Epub ahead of print]

PMID:
30553055
5.

Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease.

Alfani R, Vassallo E, De Anseris AG, Nazzaro L, D'Acunzo I, Porfito C, Mandato C, Vajro P.

Children (Basel). 2018 Dec 13;5(12). pii: E169. doi: 10.3390/children5120169. Review.

6.

Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome.

Barrea L, Annunziata G, Muscogiuri G, Di Somma C, Laudisio D, Maisto M, de Alteriis G, Tenore GC, Colao A, Savastano S.

Nutrients. 2018 Dec 13;10(12). pii: E1971. doi: 10.3390/nu10121971.

7.

Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.

Karimi-Sales E, Ebrahimi-Kalan A, Alipour MR.

Biomed Pharmacother. 2019 Jan;109:1306-1312. doi: 10.1016/j.biopha.2018.10.196. Epub 2018 Nov 9.

PMID:
30551380
8.

Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes.

Dokumacioglu E, Iskender H, Musmul A.

Biomed Pharmacother. 2019 Jan;109:1206-1210. doi: 10.1016/j.biopha.2018.10.192. Epub 2018 Nov 7.

PMID:
30551370
9.

Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.

Lai LL, Yusoff WNIW, Vethakkan SR, Mustapha NRN, Mahadeva S, Chan WK.

J Gastroenterol Hepatol. 2018 Dec 14. doi: 10.1111/jgh.14577. [Epub ahead of print]

PMID:
30551263
10.

Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials.

Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; NASH CRN.

Hepatology. 2018 Dec 14. doi: 10.1002/hep.30418. [Epub ahead of print]

PMID:
30549292
11.

MicroRNAs: Unfolding the link between inositol-requiring enzyme 1α and fatty liver.

Liu X, Green RM.

Hepatology. 2018 Dec 14. doi: 10.1002/hep.30427. [Epub ahead of print]

PMID:
30549277
12.

Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes.

Mantovani A.

Liver Int. 2018 Dec 12. doi: 10.1111/liv.14019. [Epub ahead of print]

PMID:
30548562
13.

Fibrinolytic Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation.

Nicolau-Raducu R, Beduschi T, Vianna R, Diez C, Sleem M, Bhavnha S, Vasileiou G, Raveh Y.

Liver Transpl. 2018 Dec 7. doi: 10.1002/lt.25394. [Epub ahead of print]

PMID:
30548128
14.

Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.

Breher-Esch S, Sahini N, Trincone A, Wallstab C, Borlak J.

BMC Med Genomics. 2018 Dec 14;11(1):111. doi: 10.1186/s12920-018-0438-7.

15.

Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.

Chongmelaxme B, Phisalprapa P, Manthaisong R, Dilokthornsakul P, Chaiyakunapruk N.

Pharmacoeconomics. 2018 Dec 13. doi: 10.1007/s40273-018-0754-y. [Epub ahead of print]

PMID:
30547370
16.

Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports.

Shibata Y, Nakatsuka A, Eguchi J, Miyamoto S, Masuda Y, Awazawa M, Takaki A, Yoshida R, Yagi T, Wada J.

J Med Case Rep. 2018 Dec 14;12(1):368. doi: 10.1186/s13256-018-1901-y.

17.

Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study.

Wang Q, Zheng D, Liu J, Fang L, Li Q.

Lipids Health Dis. 2018 Dec 13;17(1):284. doi: 10.1186/s12944-018-0932-0.

18.

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.

Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL.

Int J Mol Sci. 2018 Dec 10;19(12). pii: E3966. doi: 10.3390/ijms19123966. Review.

19.

Liver Fat Content and Body Fat Distribution in Youths with Excess Adiposity.

Ramírez-Vélez R, Izquierdo M, Correa-Bautista JE, Correa-Rodríguez M, Schmidt-RioValle J, González-Jiménez E, González-Jiménez K.

J Clin Med. 2018 Dec 7;7(12). pii: E528. doi: 10.3390/jcm7120528.

20.

Subterminal hydroxyeicosatetraenoic acids: Crucial lipid mediators in normal physiology and disease states.

Shoieb SM, El-Sherbeni AA, El-Kadi AOS.

Chem Biol Interact. 2018 Dec 10. pii: S0009-2797(18)31315-2. doi: 10.1016/j.cbi.2018.12.004. [Epub ahead of print] Review.

PMID:
30543782

Supplemental Content

Loading ...
Support Center